Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25751787 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24239542 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL12227671 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL22021019 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL25446681 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24004407 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24004417 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL24239885 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL23692740 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL20713635 | 1.00 | ALDH1A1 (0.62) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | ALDH1A1 3655/4885THRB 1793/4885MAPK1 2043/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | ALDH1A1 4520/4885THRB 1640/4885MAPK1 3302/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | ALDH1A1 4368/4885THRB 1271/4885MAPK1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.